amount of alcohol consumption or an effect on MF-specific survival. Consequently, it is unlikely that alcohol consumption confers a true protective benefit in MF progression. Comorbidities, including hypertension, hyperlipidemia, diabetes, obesity, solid tumor cancer, leukemia or lymphoma, autoimmune disease, and smoking, did not affect PFS in MF patients from our cohort. While heart disease was associated with shorter PFS on univariate analysis, this association disappeared with multivariate modeling.This study provides further information on potential factors that are associated with disease progression in MF. While the presence of various comorbidities did not exhibit a significant association with MF PFS or mortality, clinicians should continue to monitor these factors as they could impact the overall health and quality of life of the patients. Furthermore, patients can be reassured that these comorbidities are not associated with the progression of MF.Although this is a large MF cohort with comprehensive chart review, patients who receive primary care outside our system may not have had complete medical and social histories fully documented in their chart, potentially limiting our ability to detect more subtle associations with PFS. Future studies are needed to determine if other factors, such as exposure to environmental carcinogens, affect MF incidence or PFS.